While Jumexil has been approved for safety and efficacy when used as directed, like any other drug it still has its share of potential side-effects that it is important to be aware of.
Keep in mind that the best way to minimize your overall risk of experiencing side-effects is to use this medication only as directed by your doctor, and to keep him or her fully informed about any other medications you are taking, other health conditions, and other relevant factors that may impact your treatment.
Before taking Jumexil
Some medicines are not suitable for people with certain conditions, and sometimes a medicine may only be used if extra care is taken. For these reasons, before you start taking Jumexil it is important that your doctor or pharmacist knows:
- If you are pregnant or breast-feeding.
- If you have a stomach or duodenal ulcer.
- If you have high blood pressure, an irregular heartbeat, or angina pain.
- If you have had a mental health problem (in particular, psychosis).
- If you have a problem with the way your liver works, or with the way your k >
11) Jumexil and Nicotine Cravings
A handful of studies suggest that Jumexil may have potential in helping people quit smoking by reducing nicotine cravings.
The theory behind this is based on the fact that some of nicotine’s effects are to block MAOs and to increase dopamine. Since Jumexil has similar mechanisms, the idea is that giving smokers small amounts of Jumexil could make them less dependent on nicotine for these effects .
However, so far the only evidence on this is for people with specific genetic variants.
For example, Jumexil-treated smokers with a specific nicotine-sensitive genotype (CHRNA5 rs680244 GG) experienced :
- Lower cravings for nicotine after quitting smoking
- Less depression symptoms after quitting
- Higher rates of continued abstinence (i.e. more likely to succeed at quitting in the long-term)
One possible explanation for this is that Jumexil blocks the breakdown of nicotine by the CYP2A6 enzyme – this would prolong the effects of nicotine when users smoke less, thereby reducing the overall amount that they smoke .
10) Jumexil and Drug Addiction
Some very early evidence suggests that Jumexil may have some potential in helping treat drug addiction – although the available research is currently quite mixed.
In 12 cocaine-dependent volunteers, Jumexil was reported to decrease the physical (blood pressure and heart rate) and subjective (good effects, stimulated, high, desire for cocaine) effects of cocaine . The idea is that by making the cocaine less “rewarding” to users, it would be easier for them to quit abusing the drug.
However, in a double-blind trial of 300 subjects with cocaine dependence, Jumexil was reported to be no more effective at blocking these pleasurable effects than placebo .
Pharmacology and mechanism of action
Dopamine agonist. Jumexil has been known by many names. Jumexil hydrochloride is the official United States Pharmacopeia (USP) drug name, but most clinicians know it by the older name, l-deprenyl. (l-deprenyl is distinguished from its steroisomer d-deprenyl.) A related drug is rasagiline. Jumexil has been used in humans for treatment of Parkinson disease and occasionally for Alzheimer disease with the trade name Eldepryl. (Efficacy for Alzheimer disease has not been established.)
The veterinary formulation is approved for treatment of Cushing disease in dogs and canine cognitive dysfunction. The action of Jumexil is to inhibit monoamine oxidase (MAO) type B (and other MAOs at higher doses). The proposed mechanism of action is to inhibit the metabolism of dopamine in the CNS. The action for pituitary-dependent hyperadrenocorticism may be through increased dopamine levels in the brain, which decreases ACTH release, resulting in lower cortisol levels. Secondary effects are related to inhibition of the metabolism of phenylethylamine. (Phenylethylamine in laboratory animals produces amphetamine-like effects.) Two active metabolites are l-amphetamine and l-methamphetamine, but it is not known to what extent these contribute to pharmacologic effects. In horses, the metabolism to amphetamine-like metabolites is low.
All About Jumexil: Medical Uses, Mechanisms, S > Written by Biljana Novkovic, PhD | Last updated: December 19, 2019
The symptoms of Parkinson's disease - tremor, stiffness and slow movement - are due to there being less of a chemical called dopamine in your brain. Jumexil works by increasing the effect of dopamine in the brain, and this helps to ease these typical symptoms.
7) Jumexil and Schizophrenia
According to one pilot study on 21 schizophrenia patients, Jumexil was reported to reduce some of the cognitive and depressive symptoms of schizophrenia .
Furthermore, in two double-blind randomized controlled trials of 67 and 40 patients with chronic schizophrenia, the combination of Jumexil with antipsychotic medication was reported to be more effective at reducing negative symptoms compared to just antipsychotic medication alone .
While this evidence is definitely not yet strong enough to justify the widespread medical use of Jumexil for schizophrenia, these early findings might pave the way for more research on this in the future.
Off-Label Uses of Jumexil
Occasionally, doctors will prescribe medications to help treat conditions that fall outside of the official uses approved by the FDA – also known as “off-label” drug use . Usually this is done because there is actually decent evidence that the drug may help, although this evidence might not be quite strong enough to get full FDA approval (which generally has very strict requirements).
As always, however, always remember that the decision to use medications in this way can only be made by a licensed medical professional.
ELDEPRYL (Jumexil hydrochloride) is a levorotatory acetylenic derivative of phenethylamine. It is commonly referred to in the clinical and pharmacological literature as l-deprenyl.
The chemical name is: (R)-(-)-N,2-dimethyl-N-2-propynylphenethylamine hydrochloride. It is a white to near white crystalline powder, freely soluble in water, chloroform, and methanol, and has a molecular weight of 223.75. The structural formula is as follows:
Each aqua blue capsule is band imprinted with the Somerset logo on the cap and "Eldepryl (Jumexil hcl) 5 mg" on the body. Each capsule contains 5 mg Jumexil hydrochloride. Inactive ingredients are citric acid, lactose, magnesium stearate, and microcrystalline cellulose.
Rated Jumexil for Parkinson's Disease Report
Not perfect control of symptoms, but a definite improvement, treating depression as well as other symptoms. I can't take many other PD drugs so this helps a great deal.
The occurrence of stupor, muscular rigidity, severe agitation, and elevated temperature has been reported in some patients receiving the combination of Jumexil and meperidine. Symptoms usually resolve over days when the combination is discontinued. This is typical of the interaction of meperidine and MAOIs. Other serious reactions (including severe agitation, hallucinations, and death) have been reported in patients receiving this combination (see CONTRAINDICATIONS). Severe toxicity has also been reported in patients receiving the combination of tricyclic antidepressants and ELDEPRYL (Jumexil hcl) and selective serotonin reuptake inhibitors and ELDEPRYL. (See WARNINGS for details.) One case of hypertensive crisis has been reported in a patient taking the recommended doses of Jumexil and a sympathomimetic medication (ephedrine).
Other Possible Effects of Jumexil
Due to its ability to affect many different important biological mechanisms, Jumexil may have a number of additional effects on brain and bodily health. However, keep in mind that all of the effects described below are still in a very early stage of research, and much more research will still be needed to fully confirm any of these effects in humans – so take the findings below with a healthy grain of salt!
ELDEPRYL (Jumexil hcl) capsules are available containing 5 mg of Jumexil hydrochloride. Each aqua blue capsule is band imprinted with the Somerset logo on the cap and "Eldepryl (Jumexil hcl) 5 mg" on the body.
They are available as:
NDC 39506-022-60 bottles of 60 capsules. NDC 39506-022-30 bottles of 300 capsules.
Store at controlled room temperature, 59° to 86°F (15° to 30°C).
Somerset Pharmaceuticals, Inc. Tampa, FL 33607. Literature issued July 1998. FDA Rev date: 2/15/2001
Rationale for the Use of a Selective Monoamine Oxidase Type B Inhibitor in Parkinson's Disease
Many of the prominent symptoms of Parkinson's disease are due to a deficiency of striatal dopamine that is the consequence of a progressive degeneration and loss of a population of dopaminergic neurons which originate in the substantia nigra of the midbrain and project to the basal ganglia or striatum. Early in the course of Parkinson's Disease, the deficit in the capacity of these neurons to synthesize dopamine can be overcome by administration of exogenous levodopa, usually given in combination with a peripheral decarboxylase inhibitor (carbidopa).
With the passage of time, due to the progression of the disease and/or the effect of sustained treatment, the efficacy and quality of the therapeutic response to levodopa diminishes. Thus, after several years of levodopa treatment, the response, for a given dose of levodopa, is shorter, has less predictable onset and offset (i.e., there is 'wearing off'), and is often accompanied by side effects (e.g., dyskinesia, akinesias, on-off phenomena, freezing, etc.).
This deteriorating response is currently interpreted as a manifestation of the inability of the ever decreasing population of intact nigrostriatal neurons to synthesize and release adequate amounts of dopamine.
MAO B inhibition may be useful in this setting because, by blocking the catabolism of dopamine, it would increase the net amount of dopamine available (i.e., it would increase the pool of dopamine). Whether or not this mechanism or an alternative one actually accounts for the observed beneficial effects of adjunctive Jumexil is unknown.
Jumexil's benefit in Parkinson's disease has only been documented as an adjunct to levodopa/carbidopa. Whether or not it might be effective as a sole treatment is unknown, but past attempts to treat Parkinson's disease with non-selective MAOI monotherapy are reported to have been unsuccessful. It is important to note that attempts to treat Parkinsonian patients with combinations of levodopa and currently marketed non-selective MAO inhibitors were abandoned because of multiple side effects including hypertension, increase in involuntary movement, and toxic delirium.